Insurance Dropped Your GLP-1? What to Do Next

Written by the GLP-1 Coach editorial team. Last updated August 14, 2026.

You had coverage. Now you don't — the formulary changed, your employer switched pharmacy benefit managers, your plan requires prior authorization you can't clear, or coverage was pulled entirely. This is one of the most common reasons people end up stopping a GLP-1, and it's rarely framed as the logistical and medical question it actually is.

Here's the practical playbook, ordered roughly by what to try first, along with an honest look at what each option realistically produces.

How common is losing GLP-1 coverage?

More common than the headlines suggest. A June 2025 report from Prime Therapeutics — one of the largest US pharmacy benefit managers — tracked adults who started a GLP-1 for obesity (not diabetes) over three years:

Time since starting	% still on therapy
6 months	47%
1 year	29%
2 years	15%

Not every discontinuation was involuntary, but insurance and cost are the two most common documented drivers. A 2025 national survey of US adults who discontinued a GLP-1 cited these reasons:

• Cost: 36.1%
• Side effects: 33.3%
• Lack of insurance coverage: 28.2%
• Reached weight-loss goal: 26.1%
• Other reasons: various, smaller shares

Complementary KFF (Kaiser Family Foundation) polling in 2025 found similar patterns among ever-users, with cost and coverage together representing the largest categorical reason for stopping.

The important read: losing coverage is not an outlier scenario. It is one of the modal experiences of GLP-1 use in the US in 2026. Everything that follows is written with that reality in mind.

Step 1: Confirm what actually changed

Before assuming coverage is gone, verify what specifically happened:

• Formulary tier change — the drug is still covered but at a higher copay tier. A change from $30 to $150 per month is a coverage change even if technically the drug is "covered."
• Prior authorization requirement added or tightened — coverage exists on paper but requires clinical documentation your prescriber hasn't yet submitted.
• Step therapy requirement added — the plan requires you to try (and fail) other therapies before covering the GLP-1. Sometimes this can be waived by demonstrating prior use.
• Removed from formulary entirely — the drug is no longer covered under any circumstances by this plan.
• Employer plan changed — the plan itself is different, not just the coverage decision within it.

The first phone call is to your pharmacy benefit manager (PBM) — the customer service number is on the back of your insurance card, or on the manufacturer's savings card portal if you were using one. Ask specifically: "What is the coverage status of [medication name and dose] under my current plan, and what were the details of any recent change?"

Do not assume the answer from the pharmacy — pharmacy-side error messages ("not covered" or "requires prior auth") are common when the actual coverage picture is more nuanced.

Step 2: File a written appeal if the denial has clinical merit

Every commercial and Medicare plan has a formal appeals process, and appeals are the single highest-leverage action for many people who lose coverage.

The typical appeals process:

1. Internal appeal, first level — a written request to the plan's medical review board, supported by a letter of medical necessity from your prescriber. This letter should specifically address the plan's clinical criteria for coverage.
2. Internal appeal, second level — some plans allow a second internal review with additional documentation.
3. External review — most commercial plans and Medicare must offer an independent external review by a physician not employed by the plan. This is often the point at which denials get overturned, particularly when the clinical case is strong.

The strength of the appeal depends heavily on the specifics of your situation — how well-documented your diagnosis is, what other therapies you've tried, whether you have comorbidities (like sleep apnea, hypertension, or diabetes) that add weight to the medical necessity argument, and how thorough your prescriber's letter is.

For structural guidance on the appeals process, the Obesity Action Coalition and the Obesity Medicine Association both publish patient-facing resources with template letters and step-by-step instructions. These are among the most credible non-clinician sources on this specific topic.

Step 3: Explore manufacturer patient assistance and savings programs

Both major GLP-1 manufacturers offer patient support programs that can significantly reduce out-of-pocket cost for people meeting eligibility criteria. Program specifics change frequently — always verify directly on the manufacturer's website rather than relying on third-party summaries.

Novo Nordisk (Ozempic, Wegovy, Rybelsus) offers:

• NovoCare Patient Assistance Program — income-qualifying free medication for eligible uninsured or underinsured patients.
• Ozempic and Wegovy savings cards — reduced copays for commercially-insured patients, subject to eligibility and plan restrictions.

Eli Lilly (Mounjaro, Zepbound) offers:

• Lilly Cares Foundation Patient Assistance Program — income-qualifying free medication.
• LillyDirect — a direct-to-patient pharmacy channel offering self-pay pricing that may be lower than uninsured retail pricing.
• Zepbound savings card program for commercially-insured patients.

These programs are meaningful for a portion of patients — several hundred dollars per month of savings is common for those who qualify — but they are not universal solutions. Income limits, insurance-status requirements, and plan restrictions all apply.

Step 4: Consider formulary alternatives — but understand the trade-off

If your plan doesn't cover the specific GLP-1 you were on but does cover a different one, switching may be a workable path. Common substitutions your plan may prefer:

• Wegovy → Ozempic (same molecule, weight-management → diabetes label) if you have a diabetes diagnosis.
• Zepbound → Mounjaro (same molecule, weight-management → diabetes label) same caveat.
• Injectable → oral (Wegovy or Ozempic → Rybelsus, or Foundayo/orforglipron — the new oral GLP-1 pill) — different pharmacology and different clinical profile, but a potentially cheaper covered alternative.

The trade-off worth naming: dose availability, formulation, and delivery route are not interchangeable across GLP-1s. Ozempic tops out at 2 mg weekly; Wegovy at 2.4 mg. The Ozempic ceiling is lower than the Wegovy target dose, so switching to a diabetes-labeled version may reduce total efficacy for people who were at the top of the Wegovy dose curve.

This is a decision to make with your prescriber, not through pharmacy trial-and-error.

Step 5: If cash-pay is on the table, do the math honestly

For people without meaningful patient assistance eligibility, cash-pay pricing has become more transparent and more competitive since 2024. Novo Nordisk and Eli Lilly both offer direct-to-patient self-pay channels at prices below traditional uninsured retail.

The cost math generally lands somewhere in the following range (specifics change; check current pricing):

• Manufacturer direct self-pay: several hundred dollars per month, varying by dose.
• Traditional retail without insurance: typically higher than manufacturer direct.
• Compounded semaglutide (see next section for regulatory context): variable, generally lower, with meaningful caveats.

Whether cash-pay is a workable option depends entirely on your budget and how long the coverage gap is expected to last. A six-month gap at manufacturer self-pay is different from an indefinite gap at the same price.

Step 6: Understand where compounded GLP-1s stand in 2026

This is one of the most misunderstood parts of the current landscape.

Compounding for FDA drug-shortage-listed medications was broadly permitted during the acute semaglutide and tirzepatide shortages of 2022–2024, and a substantial market of compounded GLP-1s developed as a result. Once the FDA officially removed semaglutide and tirzepatide from the drug shortage list in late 2024 and 2025, the regulatory basis for that broad compounding was substantially curtailed.

As of mid-2026, the situation is:

• Broad compounding on shortage grounds is no longer permitted for semaglutide or tirzepatide.
• Narrower compounding under personalization exceptions (different dose, different formulation, addressing a specific patient allergy) may still be available in some contexts.
• Legal challenges and enforcement actions continue to shape the specific boundaries — this is an actively contested regulatory space, not a settled one.

The practical implication: if a compounding pharmacy is offering semaglutide or tirzepatide at meaningfully lower prices with easy access in 2026, it is worth verifying they are operating within the current regulatory framework and that the product is what they say it is. This is not a general endorsement of avoidance — legitimate 503A compounding continues to serve real clinical needs — but it is a caution that the "compounded semaglutide" ecosystem that existed in 2023 is not the same ecosystem that exists in 2026.

Step 7: Consider bridge medications during a coverage gap

If none of the above produces a workable path back to a GLP-1, other medications may be able to preserve some benefit during the gap:

• Metformin — well-established, generally covered by most plans at low cost, produces modest weight benefit and meaningful glucose benefit for T2D patients.
• SGLT2 inhibitors (empagliflozin, dapagliflozin) — modest weight loss, meaningful glucose and cardiovascular benefit; often covered.
• DPP-4 inhibitors (sitagliptin) — modest glucose benefit, minimal weight benefit; often covered.
• Older weight-management medications — phentermine (short-term use), naltrexone/bupropion (Contrave), orlistat — meaningfully less effective than GLP-1s but potentially covered and available.

None of these produces GLP-1-level results. For people whose weight loss was substantial on a GLP-1, moving to any of the alternatives will typically result in some regain. But some clinical benefit — particularly for glucose control in T2D — is meaningfully better than no treatment during the gap.

What if you have to stop entirely

For a substantial fraction of people, none of the above will work out on any reasonable timeline. Coverage is gone, cash-pay isn't feasible, patient assistance doesn't apply, alternatives aren't attractive.

In that case, the transition off a GLP-1 has a predictable shape and is well-understood — it is not an emergency, it is not clinically dangerous in the acute sense, and the framework for managing it (protein target, meal structure, resistance activity, weekly weight tracking, honest habit maintenance) applies exactly as it does to any other cessation. See our week-by-week timeline for the practical playbook. If the coverage gap is going to be temporary and you plan to resume, restarting Ozempic after a break explains re-titration timelines and what to expect from a second course.

An unplanned stop is harder than a planned one, primarily because there was no runway to build the habit stack that carries loss forward. But it is not fundamentally different, and the interventions that protect against regain are within reach of most people even in the middle of a difficult coverage transition.

The bottom line

Bottom line: Losing GLP-1 coverage is one of the most common reasons people stop — cited by roughly a quarter of discontinuers, and part of why only 15% of obesity-indicated starters are still on therapy at 2 years. The playbook: confirm what actually changed, file a written appeal with a letter of medical necessity if there's clinical merit, explore manufacturer patient assistance and self-pay channels, consider formulary alternatives with your prescriber, and — if none of those work — treat the transition off as a planned event using the standard framework rather than an emergency.

Related tool: our free post-therapy timeline calculator covers the week-by-week transition after your last dose, whether the stop was planned or forced.

Final Thoughts

Coverage loss for GLP-1s is not a personal failure or an edge case — it is a structural feature of how these medications are being managed by insurers and employers in the current US healthcare landscape. Treating it as a solvable logistical problem (with a documented process, clear escalation paths, and known alternatives) rather than as an individual crisis is often the framing shift that makes it manageable.

None of what's above is a substitute for the specific conversations that need to happen — with your prescriber about clinical alternatives, with your PBM about the exact coverage change, and where relevant with a patient advocate or the Obesity Action Coalition about appeals. What this article can do is name the options and the sequence to try them in, so the first response to a denial letter isn't "what now" but "OK, step one is to call the PBM."

If the whole path leads to stopping the medication for now, that transition is well-understood and well-supported by both the evidence base and the practical playbook that exists for GLP-1 cessation. The habits and structure you built while the medication was doing its work are what carry the weight loss forward — regardless of whether the stop was planned, forced, or somewhere in between. Life after Ozempic: how to maintain weight loss after stopping covers that transition in full, including what tends to happen in the first 8–12 weeks off medication.

---

Related:

• Restarting Ozempic After a Break: Does It Still Work?
• Life After Ozempic: How to Maintain Weight Loss After Stopping GLP-1 Medication
• Orforglipron vs Ozempic: What the Head-to-Head Study Actually Shows

---

This article is educational and not a substitute for medical, legal, or insurance advice. Insurance coverage decisions, appeals processes, and medication changes are individual matters that should be handled with your prescriber, your insurance plan's member services, and where appropriate a licensed patient advocate.

Sources: Prime Therapeutics GLP-1 3-year persistence report, June 2025; KFF Health Tracking Poll on prescription drug costs and GLP-1 use, 2025; Discontinuation of GLP-1 RAs among US adults — national survey, PubMed 2025; Obesity Action Coalition; NovoCare Patient Assistance; LillyDirect and Lilly Cares Foundation.